{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:27:20Z","timestamp":1790681240773,"version":"4.1.0"},"reference-count":91,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University Medical Centre Ljubljana","award":["20210022"],"award-info":[{"award-number":["20210022"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Elevated low density lipoprotein (LDL) cholesterol and lipoprotein(a) (Lp(a)) levels have an important role in the development and progression of atherosclerosis, followed by cardiovascular events. Besides statins and other lipid-modifying drugs, PCSK9 monoclonal antibodies are known to reduce hyperlipidemia. PCSK9 monoclonal antibodies decrease LDL cholesterol levels through inducing the upregulation of the LDL receptors and moderately decrease Lp(a) levels. In addition, PCSK9 monoclonal antibodies have shown non-lipid effects. PCSK9 monoclonal antibodies reduce platelet aggregation and activation, and increase platelet responsiveness to acetylsalicylic acid. Evolocumab as well as alirocumab decrease an incidence of venous thromboembolism, which is associated with the decrease of Lp(a) values. Besides interweaving in haemostasis, PCSK9 monoclonal antibodies play an important role in reducing the inflammation and improving the endothelial function. The aim of this review is to present the mechanisms of PCSK9 monoclonal antibodies on the aforementioned risk factors.<\/jats:p>","DOI":"10.3390\/jcm11133625","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T21:25:00Z","timestamp":1656019500000},"page":"3625","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall"],"prefix":"10.3390","volume":"11","author":[{"given":"Sabina","family":"Ugov\u0161ek","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9907-3522","authenticated-orcid":false,"given":"Miran","family":"\u0160ebe\u0161tjen","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"},{"name":"Department of Cardiology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia"},{"name":"Department of Vascular Diseases, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics\u20142019 update: A report from the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5482\/HAMO-13-07-0039","article-title":"Inflammation and coagulation in atherosclerosis","volume":"33","author":"Krychtiuk","year":"2013","journal-title":"H\u00e4mostaseologie"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: Pathophysiological, genetic, and therapeutic insights: A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Chapman","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000356856","article-title":"Cholesterol: The Good, the Bad, and the Ugly\u2014Therapeutic Targets for the Treatment of Dyslipidemia","volume":"23","author":"Elshourbagy","year":"2013","journal-title":"Med. Princ. Pract."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jacl.2021.02.005","article-title":"Circulating levels of proprotein convertase subtilisin\/kexin type 9 (PCSK9) are associated with monocyte subsets in patients with stable coronary artery disease","volume":"15","author":"Krychtiuk","year":"2021","journal-title":"J. Clin. Lipidol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.2021-8-3","article-title":"New and emerging lipid-modifying drugs to lower LDL cholesterol","volume":"10","author":"Kosmas","year":"2021","journal-title":"Drugs Context"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: The DA VINCI study","volume":"28","author":"Ray","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pcad.2020.04.004","article-title":"What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?","volume":"63","author":"Cybulska","year":"2020","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: Current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.jacc.2009.12.048","article-title":"The Mysteries of Lipoprotein(a) and Cardiovascular Disease Revisited","volume":"55","author":"Kiechl","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00041433-199408000-00002","article-title":"Atherosclerosis and arterial influx of lipoproteins","volume":"5","author":"Nordestgaard","year":"1994","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A Test in Context: Lipoprotein(a): Diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11883-019-0803-9","article-title":"Looking at Lp(a) and Related Cardiovascular Risk: From Scientific Evidence and Clinical Practice","volume":"21","author":"Stulnig","year":"2019","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1002\/jcp.26050","article-title":"Lipoprotein(a): A missing culprit in the management of athero-thrombosis?","volume":"233","author":"Ferretti","year":"2017","journal-title":"J. Cell. Physiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"909","DOI":"10.5551\/jat.55400","article-title":"An Update on the Role of PCSK9 in Atherosclerosis","volume":"27","author":"Yurtseven","year":"2020","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2217\/fca-2018-0067","article-title":"Inclisiran for the treatment of cardiovascular disease: The ORION clinical development program","volume":"14","author":"Stoekenbroek","year":"2018","journal-title":"Futur. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis as an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fcvm.2019.00016","article-title":"Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease","volume":"6","author":"Aday","year":"2019","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJM199902113400607","article-title":"Acute-Phase Proteins and Other Systemic Responses to Inflammation","volume":"340","author":"Gabay","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Levstek, T., Podkraj\u0161ek, N., Likozar, A.R., \u0160ebe\u0161tjen, M., and Podkraj\u0161ek, K.T. (2022). The Influence of Treatment with PCSK9 Inhibitors and Variants in the CRP (rs1800947), TNFA (rs1800629), and IL6 (rs1800795) Genes on the Corresponding Inflammatory Markers in Patients with Very High Lipoprotein(a) Levels. J. Cardiovasc. Dev. Dis., 9.","DOI":"10.3390\/jcdd9050127"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/HJR.0b013e328308bb8b","article-title":"C-reactive protein, insulin resistance and risk of cardiovascular disease: A population-based study","volume":"15","author":"Jeppesen","year":"2008","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e005077","DOI":"10.1161\/JAHA.116.005077","article-title":"Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial","volume":"6","author":"Held","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/dom.12536","article-title":"Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: A systematic review and meta-analysis of clinical trials","volume":"17","author":"Sahebkar","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3909\/ricm19S1S0002","article-title":"PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety","volume":"19","author":"Roth","year":"2018","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Barale, C., Melchionda, E., Morotti, A., and Russo, I. (2021). PCSK9 Biology and Its Role in Atherothrombosis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115880"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/eurheartj\/ehv637","article-title":"Prognostic value of PCSK9 levels in patients with acute coronary syndromes","volume":"37","author":"Gencer","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3109\/07853890.2015.1042908","article-title":"Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease","volume":"47","author":"Li","year":"2015","journal-title":"Ann. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijcard.2016.10.084","article-title":"Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study","volume":"227","author":"Navarese","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e023328","DOI":"10.1161\/JAHA.121.023328","article-title":"Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis","volume":"11","author":"Punch","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e022348","DOI":"10.1136\/bmjopen-2018-022348","article-title":"Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: A systematic review and meta-analysis of randomised controlled trials","volume":"8","author":"Cao","year":"2018","journal-title":"BMJ Open"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1093\/eurheartj\/ehy862","article-title":"Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin\/kexin type 9 antibody treatment","volume":"40","author":"Stiekema","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1016\/j.jcmg.2019.06.022","article-title":"PCSK9 Antibody Alirocumab Attenuates Arterial Wall Inflammation Without Changes in Circulating Inflammatory Markers","volume":"12","author":"Hoogeveen","year":"2019","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/eurheartj\/ehaa171","article-title":"Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a)","volume":"41","author":"Stiekema","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100091","DOI":"10.1016\/j.ajpc.2020.100091","article-title":"C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV","volume":"3","author":"Nelson","year":"2020","journal-title":"Am. J. Prev. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Nicholls, S.J., Kataoka, Y., Nissen, S.E., Prati, F., Windecker, S., Puri, R., Hucko, T., Aradi, D., Herrman, J.-P.R., and Hermanides, R.S. (2022). Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. JACC Cardiovasc. Imaging, in press.","DOI":"10.1016\/j.hlc.2022.06.335"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3346\/jkms.2015.30.9.1213","article-title":"Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic Approaches","volume":"30","author":"Park","year":"2015","journal-title":"J. Korean Med. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1161\/01.ATV.0000051384.43104.FC","article-title":"Endothelial Dysfunction: A marker of atherosclerotic risk","volume":"23","author":"Bonetti","year":"2003","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1161\/hc4601.099485","article-title":"Cardiovascular events in patients with coronary artery disease","volume":"104","author":"Heitzer","year":"2001","journal-title":"Circulation"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jacl.2018.02.004","article-title":"Improved endothelial function after short-term therapy with evolocumab","volume":"12","author":"Maulucci","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.jacc.2003.08.066","article-title":"High lipoprotein(a) levels and small apolipoprotein(a) sizes are associated with endothelial dysfunction in a multiethnic cohort","volume":"43","author":"Wu","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.thromres.2020.07.049","article-title":"Endothelial function improvement in patients with familial hypercholesterolemia receiving PCSK-9 inhibitors on top of maximally tolerated lipid lowering therapy","volume":"194","author":"Gentile","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Metzner, T., Leitner, D.R., Dimsity, G., Gunzer, F., Opriessnig, P., Mellitzer, K., Beck, A., Sourij, H., Stojakovic, T., and Deutschmann, H. (2022). Short-Term Treatment with Alirocumab, Flow-Dependent Dilatation of the Brachial Artery and Use of Magnetic Resonance Diffusion Tensor Imaging to Evaluate Vascular Structure: An Exploratory Pilot Study. Biomedicines, 10.","DOI":"10.3390\/biomedicines10010152"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e016263","DOI":"10.1161\/JAHA.120.016263","article-title":"Evolocumab, a PCSK9-Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living with HIV and People with Dyslipidemia","volume":"9","author":"Leucker","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"639727","DOI":"10.3389\/fcvm.2021.639727","article-title":"PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation","volume":"8","author":"Luquero","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_51","first-page":"3104","article-title":"LDL receptors, caveolae and cholesterol in endothelial dysfunction: OxLDLs accomplices or victims?","volume":"178","author":"Luchetti","year":"2020","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1038\/s41598-018-20425-x","article-title":"PCSK9 induces a pro-inflammatory response in macrophages","volume":"8","author":"Ricci","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/eurheartj\/ehx002","article-title":"PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia","volume":"38","author":"Moens","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"112460","DOI":"10.1016\/j.biopha.2021.112460","article-title":"Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players","volume":"145","author":"Marques","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11883-018-0718-x","article-title":"Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors from Molecular Biology to Clinical Translation","volume":"20","author":"Karagiannis","year":"2018","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_56","first-page":"85","article-title":"The Effect of Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors on Circulating Endothelial Progenitor Cells in Patients with Cardiovascular Disease","volume":"36","author":"Mager","year":"2021","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1056\/NEJMoa022287","article-title":"Circulating Endothelial Progenitor Cells, Vascular Function, and Cardiovascular Risk","volume":"348","author":"Hill","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.numecd.2019.09.012","article-title":"Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up","volume":"30","author":"Barale","year":"2019","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.5114\/aoms.2017.65816","article-title":"The impact of hyperglycemia and hyperlipidemia on plasma P-selectin and platelet markers after ischemic stroke","volume":"13","author":"Pawelczyk","year":"2017","journal-title":"Arch. Med. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1161\/01.CIR.0000025419.95769.F0","article-title":"Association Between Enhanced Soluble CD40L and Prothrombotic State in Hypercholesterolemia: Effects of statin therapy","volume":"106","author":"Cipollone","year":"2002","journal-title":"Circulation"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jacc.2017.11.069","article-title":"PCSK9 as a Positive Modulator of Platelet Activation","volume":"71","author":"Camera","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2174\/1573403X13666170804150954","article-title":"The Role of Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) in Cardiovascular Homeostasis: A Non-Systematic Literature Review","volume":"13","author":"Hachem","year":"2017","journal-title":"Curr. Cardiol. Rev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/ehjcvp\/pvz022","article-title":"PCSK9 and inflammation: A review of experimental and clinical evidence","volume":"5","author":"Momtazi","year":"2019","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"76","DOI":"10.5551\/jat.25841","article-title":"The Relationship between the Plasma PCSK9 Levels and Platelet Indices in Patients with Stable Coronary Artery Disease","volume":"22","author":"Li","year":"2015","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jacc.2017.07.743","article-title":"Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients with Atrial Fibrillation","volume":"70","author":"Pastori","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Puteri, M.U., Azmi, N.U., Kato, M., and Saputri, F.C. (2022). PCSK9 Promotes Cardiovascular Diseases: Recent Evidence about Its Association with Platelet Activation-Induced Myocardial Infarction. Life, 12.","DOI":"10.3390\/life12020190"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.120.046290","article-title":"PCSK9 (Proprotein Convertase Subtilisin\/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36","volume":"143","author":"Qi","year":"2021","journal-title":"Circulation"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Petersen-Uribe, A., Kremser, M., Rohlfing, A.-K., Castor, T., Kolb, K., Dicenta, V., Emschermann, F., Li, B., Borst, O., and Rath, D. (2021). Platelet-Derived PCSK9 Is Associated with LDL Metabolism and Modulates Atherothrombotic Mechanisms in Coronary Artery Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222011179"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Morofuji, Y., Nakagawa, S., Ujifuku, K., Fujimoto, T., Otsuka, K., Niwa, M., and Tsutsumi, K. (2022). Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer. Pharmaceuticals, 15.","DOI":"10.3390\/ph15020151"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"P\u0119czek, P., Le\u015bniewski, M., Mazurek, T., Szarpak, L., Filipiak, K., and G\u0105secka, A. (2021). Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia. Life, 11.","DOI":"10.3390\/life11060466"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejphar.2011.02.026","article-title":"The effect of a platelet cholesterol modulation on the acetylsalicylic acid-mediated blood platelet inhibition in hypercholesterolemic patients","volume":"658","author":"Luzak","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11239-007-0154-1","article-title":"Effect of high dose statin therapy on platelet function; statins reduce aspirin resistant platelet aggregation in patients with coronary heart disease","volume":"27","author":"Tirnaksiz","year":"2007","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1182\/blood-2016-01-631259","article-title":"Cholesterol in platelet biogenesis and activation","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1055\/s-0038-1676863","article-title":"PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention","volume":"119","author":"Paciullo","year":"2019","journal-title":"Thromb. Haemost."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Ugov\u0161ek, S., and \u0160ebe\u0161tjen, M. (2021). Lipoprotein(a)\u2014The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation. Biomolecules, 12.","DOI":"10.3390\/biom12010026"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Thematic review series: Lipoprotein (a): Coming of age at last: Lipoprotein (a): Truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J. Lipid Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","article-title":"Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of lipoprotein(a) and modification by alirocumab: Prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial","volume":"141","author":"Schwartz","year":"2020","journal-title":"Circulation"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1161\/CIRCULATIONAHA.120.046397","article-title":"The effect of PCSK9 inhibition on the risk of venous thromboembolism","volume":"141","author":"Marston","year":"2020","journal-title":"Circulation"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1182\/blood.V96.10.3364","article-title":"Increased lipo-protein (a) levels as an independent risk factor for venous thromboembolism","volume":"96","author":"Eisert","year":"2000","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.amjmed.2003.06.005","article-title":"Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism","volume":"115","author":"Marcucci","year":"2003","journal-title":"Am. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1055\/s-0032-1301420","article-title":"The Thrombophilic Pattern of Different Clinical Manifestations of Venous Thromboembolism: A Survey of 443 Cases of Venous Thromboembolism","volume":"38","author":"Grifoni","year":"2012","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/14017431.2019.1612087","article-title":"Lipoprotein(a) is not associated with venous thromboembolism risk","volume":"53","author":"Kunutsor","year":"2019","journal-title":"Scand. Cardiovasc. J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/ATVBAHA.112.248765","article-title":"Genetic Evidence That Lipoprotein(a) Associates with Atherosclerotic Stenosis Rather Than Venous Thrombosis","volume":"32","author":"Kamstrup","year":"2012","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/archinte.162.10.1182","article-title":"Cardiovascular Risk Factors and Venous Thromboembolism Incidence: The longitudinal investigation of thromboembolism etiology","volume":"162","author":"Tsai","year":"2002","journal-title":"Arch. Intern. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jth.12056","article-title":"Lipoprotein(a), polymorphisms in the LPA gene, and incident venous thromboembolism among 21 483 women","volume":"11","author":"Danik","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1160\/TH12-06-0426","article-title":"Lipid levels do not influence the risk of venous thromboembolism. Results of a population-based cohort study","volume":"108","author":"Mahmoodi","year":"2012","journal-title":"Thromb. Haemost."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1194\/jlr.P094763","article-title":"Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis","volume":"60","author":"Boffa","year":"2019","journal-title":"J. Lipid Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.biopha.2018.09.164","article-title":"No effect of PCSK9 inhibitors on D-dimer and fibrinogen levels in patients with familial hypercholesterolemia","volume":"108","author":"Kruip","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Scalise, V., Sanguinetti, C., Neri, T., Cianchetti, S., Lai, M., Carnicelli, V., Celi, A., and Pedrinelli, R. (2021). PCSK9 Induces Tissue Factor Expression by Activation of TLR4\/NFkB Signaling. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222312640"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e13459","DOI":"10.1111\/eci.13459","article-title":"PCSK9 and atherosclerosis: Looking beyond LDL regulation","volume":"51","author":"Ragusa","year":"2020","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_91","unstructured":"(2022, May 10). The Official ORION-4 Study Website. Available online: https:\/\/www.orion4trial.org\/homepage-uk."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/13\/3625\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:38:15Z","timestamp":1760139495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/13\/3625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":91,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["jcm11133625"],"URL":"https:\/\/doi.org\/10.3390\/jcm11133625","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,23]]}}}